Q-omics provides the consensus-scored CCDC85B profile across patient tissues and cancer cell-line models. CCDC85B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC85B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CCDC85B RNA expression shows 18,429 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where CCDC85B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC85B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC85B survival associations across molecular data types. CCDC85B RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC85B RNA expression–survival associations across cancer types. High CCDC85B expression shows unfavorable associations in KIRP, HNSC, LUAD, COAD and ACC, but favorable associations in SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC85B RNA expression.
This table summarizes CCDC85B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC85B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC85B shows lower tumor expression in BLCA and UCEC and higher tumor expression in COAD, KIRC, LIHC and ESCA. The COAD box plot shows higher CCDC85B RNA expression in tumor versus normal tissue (log2 FC = +2.024, t-test p < 0.001).
This table shows molecular features associated with CCDC85B in patient tissues and cancer cell lines. In patient samples, CCDC85B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC85B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
